84 A widely prescribed class of diabetes drugs may offer unexpected protection for people undergoing cancer treatment, potentially reducing their risk of heart failure and early death. The findings, drawn from a major new analysis of over 100,000 patients, suggest sodium–glucose cotransporter 2 inhibitors (SGLT2i) could play a vital role in improving outcomes for cancer patients with type 2 diabetes. The study was published in the European Heart Journal of Cardiovascular Pharmacotherapy. Many cancer treatments, including chemotherapy, are known to damage the heart. This makes cardiovascular health a major concern for patients already living with diabetes, a condition that itself increases the risk of heart disease. Researchers sought to explore whether SGLT2 inhibitors, drugs initially developed to lower blood sugar, could also guard against some of the serious heart-related complications that occur during cancer treatment. The analysis reviewed 11 observational studies, including more than 104,000 people with both cancer and diabetes. It found that patients taking SGLT2 inhibitors were significantly less likely to die from any cause than those not on the medication. In addition, they were less likely to be hospitalised for heart failure. These benefits appeared consistent even in those receiving chemotherapy drugs known for their cardiotoxicity, such as anthracyclines. The data point to a nearly 53% reduction in the risk of death and a 56% drop in heart failure hospitalisations among patients using the drug. The researchers also looked closely at patients without existing heart failure and those being treated specifically with anthracyclines. In both groups, the benefits of SGLT2 inhibitors remained apparent, strengthening the case for their protective role. The findings build on earlier research showing that SGLT2 inhibitors help reduce cardiovascular events in the general diabetic population. This new evidence now suggests that the same drugs may also counteract some of the damage inflicted by cancer therapies on the heart. As cancer survival rates improve, managing the long-term effects of treatment has become increasingly important, particularly in vulnerable patients with multiple health issues. However, experts caution that these results come from observational studies, which cannot establish cause and effect. It is possible that patients who were prescribed SGLT2 inhibitors were healthier overall or had better access to care. This means randomised controlled trials are still needed to confirm whether the drug itself offers a protective effect during cancer treatment. Importantly, the review found no evidence of increased adverse effects from taking SGLT2 inhibitors in this population. Common side effects remained limited to known issues such as urinary infections and low blood sugar, especially when combined with other diabetes drugs. While more research is needed, the study raises the possibility that a medication already in wide use could offer a simple way to improve survival and reduce heart complications in cancer patients. Several clinical trials are now underway to investigate this further, including trials specifically targeting those receiving high-risk chemotherapy. If confirmed, the protective effect of SGLT2 inhibitors could transform how doctors manage heart health in cancer patients with diabetes. The hope is that these drugs might soon serve a dual purpose: controlling blood sugar and shielding the heart from harm.